Equity Profile

IRON

Disc Medicine, Inc.

Health CareBiotechnology$3.1B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Disc Medicine, Inc. is a biotechnology company focused on developing innovative therapies for patients with rare blood disorders....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability, and investors will closely monitor this to gauge the company's financial health.

-1.74

Revenue

Although no revenue is expected this quarter, any updates on future revenue streams or partnerships could be significant for investor sentiment.

Wall Street expectations, options signals, track record, and call prep available with Pro.

IRON Q2-2026 Earnings Preview

Context

Company Snapshot

Disc Medicine, Inc. is a biotechnology company focused on developing innovative therapies for patients with rare blood disorders. As part of the health care sector, its work is crucial in addressing unmet medical needs and improving patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-39.84%

Avg Stock Reaction

+0.34%

Last Quarter Recap

In Q1-2026, Disc Medicine reported an EPS of -1.65, which was worse than the expected -1.55, leading to a slight decline in stock price the following day. Investors are looking for signs of improvement in this upcoming report.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Disc Medicine to report a loss this quarter, with a consensus EPS of -1.74. Investors are particularly focused on whether the company can show progress in its drug development pipeline.

Bull Case

If Disc Medicine can exceed EPS expectations and provide positive updates on its drug candidates, it may boost investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, if the company reports a larger loss than expected or fails to provide any new insights into its development pipeline, it could lead to a negative reaction from the market.

Key Metrics to Watch

EPS

-1.74

Earnings per share (EPS) is a key indicator of profitability, and investors will closely monitor this to gauge the company's financial health.

Revenue

Although no revenue is expected this quarter, any updates on future revenue streams or partnerships could be significant for investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of -1.74?

A better-than-expected EPS could signal improved operational efficiency or progress in drug development, which would be well-received by investors.

What updates can management provide on the drug development pipeline?

Investors are keen to hear about any advancements or setbacks in the pipeline, as this will directly impact future revenue potential and overall company valuation.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Disc Medicine to narrow its losses this quarter, given recent advancements in its drug pipeline that have not been fully factored into consensus estimates.

Supporting Evidence

The company has a history of surprising investors with better-than-expected EPS despite challenging forecasts.

Options pricing suggests a significant move, indicating that traders are anticipating more volatility than what the consensus reflects.

Key Risk

If the company can demonstrate any progress in its drug development, it could significantly shift investor sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around the company's ability to manage losses while advancing its drug development efforts.

Bull Confirmed If

An EPS of -1.50 or better, along with positive updates on drug candidates, would confirm the bull case.

Bear Confirmed If

An EPS worse than -2.00, coupled with no new information on the pipeline, would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±22.14%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±22.1% while IRON has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

32.9%

Calls (200)P/C Ratio: 1.00Puts (200)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Disc Medicine beats expectations, history suggests a potential stock increase of around 0.64%, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance from management.

Miss

A disappointing report could lead to a decline in stock price, with historical patterns suggesting an average drop of around 0.64%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the status of drug candidates in the pipeline.
2Updates on partnerships or collaborations that could enhance revenue prospects.
3Management's outlook on cost management and operational efficiency.
4Insights into market conditions affecting the biotechnology sector.
5Any changes to the company's strategic direction or focus areas.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Disc Medicine, Inc. is a biotechnology company focused on developing innovative therapies for patients with rare blood disorders....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability, and investors will closely monitor this to gauge the company's financial health.

-1.74

Revenue

Although no revenue is expected this quarter, any updates on future revenue streams or partnerships could be significant for investor sentiment.

Wall Street expectations, options signals, track record, and call prep available with Pro.

IRON Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-39.84%

Avg Stock Reaction

+0.34%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Disc Medicine can exceed EPS expectations and provide positive updates on its drug candidates, it may boost investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, if the company reports a larger loss than expected or fails to provide any new insights into its development pipeline, it could lead to a negative reaction from the market.

Key Metrics to Watch

EPS

-1.74

Earnings per share (EPS) is a key indicator of profitability, and investors will closely monitor this to gauge the company's financial health.

Revenue

Although no revenue is expected this quarter, any updates on future revenue streams or partnerships could be significant for investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of -1.74?

A better-than-expected EPS could signal improved operational efficiency or progress in drug development, which would be well-received by investors.

What updates can management provide on the drug development pipeline?

Investors are keen to hear about any advancements or setbacks in the pipeline, as this will directly impact future revenue potential and overall company valuation.

Edge

What the Street Is Missing

Why consensus could be wrong

Supporting Evidence

The company has a history of surprising investors with better-than-expected EPS despite challenging forecasts.

Options pricing suggests a significant move, indicating that traders are anticipating more volatility than what the consensus reflects.

Key Risk

If the company can demonstrate any progress in its drug development, it could significantly shift investor sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around the company's ability to manage losses while advancing its drug development efforts.

Bull Confirmed If

An EPS of -1.50 or better, along with positive updates on drug candidates, would confirm the bull case.

Bear Confirmed If

An EPS worse than -2.00, coupled with no new information on the pipeline, would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±22.14%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±22.1% while IRON has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

32.9%

Calls (200)P/C Ratio: 1.00Puts (200)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Disc Medicine beats expectations, history suggests a potential stock increase of around 0.64%, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance from management.

Miss

A disappointing report could lead to a decline in stock price, with historical patterns suggesting an average drop of around 0.64%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the status of drug candidates in the pipeline.
2Updates on partnerships or collaborations that could enhance revenue prospects.
3Management's outlook on cost management and operational efficiency.
4Insights into market conditions affecting the biotechnology sector.
5Any changes to the company's strategic direction or focus areas.